German group’s drugs chief warns EU and UK are dissuading investment as company prioritises US and China
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
Recent Posts
- Kremlin backs covert campaign to keep Orbán in power
- Lloyd’s of London says it will still insure ‘basically anyone’ in the Gulf
- People on controversial UK student loan plan each owe over £40,000 on average
- Lasers, radars and drones: Middle East war spurs hunt for cheaper air defence
- The economic consequences of war with Iran
